Since the point mutation T790M in the EGFR kinase domain is the major mechanism of resistance to EGFR-TKI therapies, it is conceivable that patients with higher pEGFRmut concentrations progress at a faster rate because of extensive tumor burden and potentially higher frequency of pretreatment T790M mutation. Here, EGFR is linked to neoplasm.